The ELISpot and FluoroSpot Assay Market is Segmented By Product (Analyzers, Assay Kits, and Ancillary Products), Application (Research and Diagnostics), End-User (Hospitals & Clinical Labs, Biopharmaceutical Companies, and Research Institutes) and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America).
The global ELISpot and FluoroSpot Assay market size was estimated at USD 295.64 million in 2023 and is projected to reach USD 503.41 million in 2030 at a CAGR of 7.9% during the forecast period 2023-2030.
Due to its excellent sensitivity, the enzyme-linked immunospot (ELISpot) test is frequently used to identify different illness conditions. They're incredibly adaptable and frequently employed to gauge antigen-specific T lymphocytes in mice and people. Because they may measure a wide range of immune responses and cellular immune-related activities, these tests are increasingly recommended and well-liked. Thus, ELISpot has now undergone a considerable transformation from a research tool to a clinical test that is often used in laboratories. Several ELISpot tests, including as those for IFN-gamma, Granzyme B, TGF-Beta 1, Fluorescent, and others, are used for a variety of diagnostic purposes. In order to conduct the FluoroSpot test, a 96-well plate containing a combination of monoclonal antibodies and PVDF membranes is used as the assay platform. For secreted proteins like cytokines from active cells, the ELISpot and FluoroSpot are ideally suited.
The worldwide ELISpot and FluoroSpot assay market is divided into infectious illnesses, cancer, autoimmune disorders, allergies, and others on the basis of diseases. The infectious illness is further divided into categories like COVID-19, the flu, HIV, and others. Due to the rising prevalence of chronic infectious illnesses and the higher productivity associated with the use of ELISpot and FluoroSpot tests, the infectious diseases sector is anticipated to dominate the ELISpot and FluoroSpot assay market in 2021. Diagnostic and research applications make up the segments of the global ELISpot and FluoroSpot assay market. Infectious illnesses, transplants, and other conditions are further divided into sub-segments within the diagnostic applications. The research applications are further divided into the following categories: cancer research, clinical trials, vaccine development, and others.
The COVID-19 pandemic had a major influence on healthcare systems across the world, including the markets for ELISpot and FluoroSpot assays. The FluoroSpot assay revealed that COVID-19 patients had the lowest antibody response, whereas three individuals (C4, C5, and C7) had the strongest T-cell responses. ELISpot and FluoroSpot tests are frequently used to evaluate COVID-19 patients' T- and B-cell immunity against SARS-CoV-2. Nonetheless, the industry has recorded a modest fall because COVID-19 instances decreased last year.
The development of new vaccines to combat drug-resistant strains, the rise in the prevalence of chronic diseases worldwide, and technical advancements in ELISpot and FluoroSpot analyzers and assay kits are anticipated to propel market expansion. ELISpot is a vital technique in the creation of vaccines against a number of diseases, such as AIDS, TB, malaria, cancer, and the flu. In clinical investigations to assess vaccinations, the ELISpot test is frequently employed. In comparison to enzyme-linked immunoassays (ELISA) and flow cytometry, the FluoroSpot test based on the ELISpot was found to be more accurate in a June 2021 paper published in the BMC Infectious Diseases Journal (FCM). More than 15 million individuals between the ages of 30 and 69 pass away from NCDs, with low- and middle-income nations accounting for 85% of these early fatalities. As a result, the use of ELISpot and FluroSpot tests for diagnostic purposes is anticipated to expand due to the rising prevalence of chronic illnesses, fueling market expansion.
North America to Dominate the Market